| Autor: |
Rosenthal, A., Jun, M., Munoz, J., Wang, T., Mutebi, A., Wang, A., Yang, S., Osei‐Bonsu, K., Elliott, B., Kalsekar, A., Navarro, F. Rivas, Ip, A. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p790-792, 3p |
| Abstrakt: |
We compared the efficacy of epcoritamab versus chimeric antigen receptor T-cell (CAR T) therapy, polatuzumab-based (pola-based) regimens, and tafasitamab-based (tafa-based) regimens in R/R diffuse large B-cell lymphoma (DLBCL) and LBCL. B Introduction: b Epcoritamab, an off-the-shelf subcutaneous CD3xCD20 T-cell-engaging, bispecific antibody that redirects CD3+ T cells to eliminate malignant CD20+ B cells, has shown deep and durable responses in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patient populations, including those with difficult-to-treat LBCL. B Results: b A total of 96 CAR T-naive LBCL patients were included in the epcoritamab cohort versus 55 in the CAR T cohort, and 139 DLBCL patients in the epcoritamab cohort versus 37 receiving pola-based and 20 receiving tafa-based regimen. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text